Healthcare expenditure on Indigenous and non-Indigenous Australians at high risk of cardiovascular disease
Authors:
- Blake AngellBABlake Angell
- Tracey-Lea LabaTLTracey-Lea Laba
- Tom LungTLTom Lung
- Alex BrownABAlex Brown
- Sandra EadesSESandra Eades
- Tim UsherwoodTUTim Usherwood
- David PeirisDPDavid Peiris
- Laurent BillotLBLaurent Billot
- Graham HillisGHGraham Hillis
- Ruth WebsterRWRuth Webster
- Andrew TonkinATAndrew Tonkin
- Christopher ReidCRChristopher Reid
Open Access
- 23 June 2017
- journal article
- research article
- Published by Springer Nature in International Journal for Equity in Health
- Vol. 16 (1) , 1-7
Abstract
In spite of bearing a heavier burden of death, disease and disability, there is mixed evidence as to whether Indigenous Australians utilise more or less healthcare services than other Australians given their elevated risk level. This study analyses the Medicare expenditure and its predictors in a cohort of Indigenous and non-Indigenous Australians at high risk of cardiovascular disease. The healthcare expenditure of participants of the Kanyini Guidelines Adherence with the Polypill (GAP) pragmatic randomised controlled trial was modelled using linear regression methods. 535 adult (48% Indigenous) participants at high risk of cardiovascular disease (CVD) were recruited through 33 primary healthcare services (including 12 Aboriginal Medical Services) across Australia. There was no significant difference in the expenditure of Indigenous and non-Indigenous participants in non-remote areas following adjustment for individual characteristics. Indigenous individuals living in remote areas had lower MBS expenditure ($932 per year P < 0.001) than other individuals. MBS expenditure was found to increase with being aged over 65 years ($128, p = 0.013), being female ($472, p = 0.003), lower baseline reported quality of life ($102 per 0.1 decrement of utility p = 0.004) and a history of diabetes ($324, p = 0.001), gout ($631, p = 0.022), chronic obstructive pulmonary disease ($469, p = 0.019) and established CVD whether receiving guideline-recommended treatment prior to the trial ($452, p = 0.005) or not ($483, p = 0.04). When controlling for all other characteristics, morbidly obese patients had lower MBS expenditure than other individuals (−$887, p = 0.002). The findings suggest that for the majority of participants, once individuals are engaged with a primary care provider, factors other than whether they are Indigenous determine the level of Medicare expenditure for each person. Australian New Zealand Clinical Trials Registry ACTRN 126080005833347.Keywords
Funding Information
- National Health and Medical Research Council (1004623)
This publication has 14 references indexed in Scilit:
- The imperative for investment in Aboriginal and Torres Strait Islander healthMedical Journal of Australia, 2014
- A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease riskEuropean Journal of Preventive Cardiology, 2014
- Health services use and lifestyle choices of Indigenous and non-Indigenous AustraliansSocial Science & Medicine, 2013
- Time Trade-Off Derived EQ-5D Weights for AustraliaValue in Health, 2011
- Contracting for Indigenous Health Care: Towards Mutual AccountabilityAustralian Journal of Public Administration, 2011
- Review of statistical methods for analysing healthcare resources and costsHealth Economics, 2010
- The cost of overweight and obesity in AustraliaMedical Journal of Australia, 2010
- Improving Indigenous patients’ access to mainstream health services: the Inala experienceMedical Journal of Australia, 2009
- Burden of disease and injury in Aboriginal and Torres Strait Islander Peoples: the Indigenous health gapInternational Journal of Epidemiology, 2008
- Smearing Estimate: A Nonparametric Retransformation MethodJournal of the American Statistical Association, 1983